Search research articles
Contact Us
Filters
Showing results (41-50 of 54) with videos related to
Page
of 6
Sort By:
Journal of Critical Care
|
September 3, 2018
Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion
Cédric Carrié, Rachel Legeron, Laurent Petit, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
November 24, 2004
Simultaneous determination of the antiretroviral agents: amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in human peripheral blood mononuclear cells by high-performance liquid chromatography-mass spectrometry
Agnès Rouzes, Karine Berthoin, Fabien Xuereb, et al.
Fundamental & Clinical Pharmacology
|
July 29, 2011
Chemotherapy and targeted agents for colorectal cancer in a real-life setting anticipate guidelines: the COLCHIC cohort study
Denis Smith, Eric Terrebonne, Magali Rouyer, et al.
AIDS (London, England)
|
July 20, 2002
Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study)
Isabelle Pellegrin, Dominique Breilh, François Montestruc, et al.
The Journal of Antimicrobial Chemotherapy
|
November 11, 2025
Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients-the PhASAge Study
Nicolas Grégoire, David Mbarga, Hélène Mirfendereski, et al.
Antiviral Therapy
|
July 22, 2006
Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study)
Isabelle Pellegrin, Dominique Breilh, Jean-Marie Ragnaud, et al.
The Journal of Antimicrobial Chemotherapy
|
April 15, 2010
HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens
Daniel da Silva, Liesbeth Van Wesenbeeck, Dominique Breilh, et al.
Antimicrobial Agents and Chemotherapy
|
February 14, 2007
Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients
Isabelle Pellegrin, Dominique Breilh, Gaelle Coureau, et al.
The Journal of Antimicrobial Chemotherapy
|
April 2, 2009
Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort
Linda Wittkop, Dominique Breilh, Daniel Da Silva, et al.
Antiviral Therapy
|
May 29, 2008
Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study)
Isabelle Pellegrin, Linda Wittkop, Laurence Morand Joubert, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 54) with videos related to
Sort By:
Page
of 6
Journal of Critical Care
|
September 3, 2018
Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion
Cédric Carrié, Rachel Legeron, Laurent Petit, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
November 24, 2004
Simultaneous determination of the antiretroviral agents: amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in human peripheral blood mononuclear cells by high-performance liquid chromatography-mass spectrometry
Agnès Rouzes, Karine Berthoin, Fabien Xuereb, et al.
Fundamental & Clinical Pharmacology
|
July 29, 2011
Chemotherapy and targeted agents for colorectal cancer in a real-life setting anticipate guidelines: the COLCHIC cohort study
Denis Smith, Eric Terrebonne, Magali Rouyer, et al.
AIDS (London, England)
|
July 20, 2002
Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study)
Isabelle Pellegrin, Dominique Breilh, François Montestruc, et al.
The Journal of Antimicrobial Chemotherapy
|
November 11, 2025
Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients-the PhASAge Study
Nicolas Grégoire, David Mbarga, Hélène Mirfendereski, et al.
Antiviral Therapy
|
July 22, 2006
Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study)
Isabelle Pellegrin, Dominique Breilh, Jean-Marie Ragnaud, et al.
The Journal of Antimicrobial Chemotherapy
|
April 15, 2010
HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens
Daniel da Silva, Liesbeth Van Wesenbeeck, Dominique Breilh, et al.
Antimicrobial Agents and Chemotherapy
|
February 14, 2007
Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients
Isabelle Pellegrin, Dominique Breilh, Gaelle Coureau, et al.
The Journal of Antimicrobial Chemotherapy
|
April 2, 2009
Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort
Linda Wittkop, Dominique Breilh, Daniel Da Silva, et al.
Antiviral Therapy
|
May 29, 2008
Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study)
Isabelle Pellegrin, Linda Wittkop, Laurence Morand Joubert, et al.
Page
of 6